These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 12369854

  • 1. Agents targeting ras signaling pathway.
    Dancey JE.
    Curr Pharm Des; 2002; 8(25):2259-67. PubMed ID: 12369854
    [Abstract] [Full Text] [Related]

  • 2. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F.
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [Abstract] [Full Text] [Related]

  • 3. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E, Kantarjian H, Cortes J.
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [Abstract] [Full Text] [Related]

  • 4. Ras family signaling: therapeutic targeting.
    Cox AD, Der CJ.
    Cancer Biol Ther; 2002 Nov; 1(6):599-606. PubMed ID: 12642680
    [Abstract] [Full Text] [Related]

  • 5. Farnesyl transferase inhibitors as anticancer agents.
    Haluska P, Dy GK, Adjei AA.
    Eur J Cancer; 2002 Sep; 38(13):1685-700. PubMed ID: 12175684
    [Abstract] [Full Text] [Related]

  • 6. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
    Baum C, Kirschmeier P.
    Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
    [Abstract] [Full Text] [Related]

  • 7. Farnesyl transferase inhibitors in the treatment of breast cancer.
    Kelland LR.
    Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
    [Abstract] [Full Text] [Related]

  • 8. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.
    End DW.
    Invest New Drugs; 1999 Mar; 17(3):241-58. PubMed ID: 10665477
    [Abstract] [Full Text] [Related]

  • 9. Farnesyltransferase inhibitors.
    Hahn SM, Bernhard E, McKenna WG.
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [Abstract] [Full Text] [Related]

  • 10. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
    Helbig G, Hołowiecki J.
    Wiad Lek; 2004 Oct; 57(9-10):462-7. PubMed ID: 15765763
    [Abstract] [Full Text] [Related]

  • 11. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
    O'Regan RM, Khuri FR.
    Endocr Relat Cancer; 2004 Jun; 11(2):191-205. PubMed ID: 15163298
    [Abstract] [Full Text] [Related]

  • 12. Inhibitors of the ras oncogene as therapeutic targets.
    Ghobrial IM, Adjei AA.
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
    Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Bishop WR.
    Cancer Res; 1998 Nov 01; 58(21):4947-56. PubMed ID: 9810004
    [Abstract] [Full Text] [Related]

  • 14. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S, Lodagala DS.
    Acta Pharmacol Sin; 2000 May 01; 21(5):396-404. PubMed ID: 11324435
    [Abstract] [Full Text] [Related]

  • 15. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE, Pfeiffer JR, Lee RJ, Kusewitt DF, Martinez AM, Foutz T, Wilson BS, Oliver JM.
    J Immunol; 1998 Dec 15; 161(12):6733-44. PubMed ID: 9862703
    [Abstract] [Full Text] [Related]

  • 16. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Li Z, Dell J, Lipari P, Malkowski M, Prioli N, Rossman RR, Korfmacher WA, Nomeir AA, Lin CC, Mallams AK, Doll RJ, Catino JJ, Girijavallabhan VM, Kirschmeier P, Bishop WR.
    Cancer Chemother Pharmacol; 1999 Dec 15; 43(1):50-8. PubMed ID: 9923541
    [Abstract] [Full Text] [Related]

  • 17. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, Lotan R, Khuri FR, Hong WK.
    J Natl Cancer Inst; 2004 Oct 20; 96(20):1536-48. PubMed ID: 15494604
    [Abstract] [Full Text] [Related]

  • 18. Blocking oncogenic Ras signaling for cancer therapy.
    Adjei AA.
    J Natl Cancer Inst; 2001 Jul 18; 93(14):1062-74. PubMed ID: 11459867
    [Abstract] [Full Text] [Related]

  • 19. Ras regulatory interactions: novel targets for anti-cancer intervention?
    Prendergast GC, Gibbs JB.
    Bioessays; 1994 Mar 18; 16(3):187-91. PubMed ID: 8166672
    [Abstract] [Full Text] [Related]

  • 20. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
    Crul M, de Klerk GJ, Beijnen JH, Schellens JH.
    Anticancer Drugs; 2001 Mar 18; 12(3):163-84. PubMed ID: 11290863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.